8-K - Galera Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On February 6, 2026, Galera Therapeutics, Inc. entered into a letter agreement with Joel Sussman, its Chief Accounting Officer, Treasurer, and Secretary, providing for up to $250,000 in aggregate retention-based cash bonus payments linked to the timely completion of certain reporting obligations.

Key Takeaways

1Agreement executed on February 6, 2026, with Joel Sussman, Chief Accounting Officer, Treasurer, and Secretary.

2Mr. Sussman is eligible to receive up to $250,000 in aggregate retention bonus payments.

3Bonuses are tied to the timely completion and filing of certain reporting obligations by the Company.

4Retention bonuses paid will reduce any severance payments under his existing employment agreement on a dollar-for-dollar basis.

5Unpaid retention bonuses are payable without conditions upon involuntary termination (other than for cause) or termination for good reason.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 6

Management Change

$250.0K

Executive & Director Changes

Joel Sussman

Chief Accounting Officer, Treasurer, and Secretary

Compensatory Arrangement

Effective: 2026-02-06

Exhibits (1)

8-K